

Annex 7

Principal Investigator's declaration for clinical research on remuneration and reporting obligations in Medsol

I, the undersigned,, as the principal investigator of the protocol, hereby declare that I accept and apply the principle of Semmelweis University for the allocation of the study fee, according to which the remaining amount of the study fee after deduction of the co-payment and the university contribution is allocated among the team members.

The fee for the performance of the principal investigator's duties shall not exceed 25% of this amount, while the remuneration of sub-investigators and pharmacists shall not be less than 5% of this amount.

(As an example: for studies with a low cost price per total fee, using the traditional multi-contracting model, these fees shall not exceed 17% and shall be at least 3.4%.)

Fees shall be set in proportion to the division of responsibilities and tasks. I further agree that it is the responsibility of the investigator to ensure that, in accordance with Government Decree 43/1999 (III.3), the status of benefits for medical research is recorded in the MedSol computer system as "B" (other funded), funder: 6 (drug research) in reimbursement category "F", and that complication benefits for medical research are reported to the National Health Insurance Fund Manager in reimbursement category "G".

The completed and signed Investigator's Declaration must be sent electronically in PDF format only to klinikaikutatas@semmelweis.hu

Date:

.....

Signature of the principal investigator